Guardant Health (NASDAQ:GH) Insider Terilyn Monroe Sells 46,300 Shares

Guardant Health, Inc. (NASDAQ:GH) insider Terilyn Monroe sold 46,300 shares of the stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $165.12, for a total value of $7,645,056.00. Following the completion of the transaction, the insider owned 22,979 shares of the company’s stock, valued at $3,794,292.48. This trade represents a 66.83% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Guardant Health Trading Down 3.4%

Shares of GH opened at $159.54 on Friday. The business’s 50-day moving average price is $149.77 and its 200 day moving average price is $116.59. The stock has a market capitalization of $21.41 billion, a P/E ratio of -45.71 and a beta of 1.60. Guardant Health, Inc. has a 1-year low of $53.40 and a 1-year high of $176.58.

Institutional Trading of Guardant Health

Several hedge funds and other institutional investors have recently modified their holdings of GH. V Square Quantitative Management LLC acquired a new position in Guardant Health in the 4th quarter worth about $27,000. Elyxium Wealth LLC acquired a new stake in shares of Guardant Health during the 4th quarter valued at about $35,000. Parallel Advisors LLC lifted its holdings in shares of Guardant Health by 164.7% during the 4th quarter. Parallel Advisors LLC now owns 352 shares of the company’s stock valued at $36,000 after buying an additional 219 shares during the last quarter. Ascentis Independent Advisors bought a new stake in shares of Guardant Health in the 1st quarter valued at approximately $38,000. Finally, Hollencrest Capital Management bought a new stake in shares of Guardant Health in the 1st quarter valued at approximately $41,000. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on GH. Canaccord Genuity Group boosted their price target on shares of Guardant Health from $135.00 to $205.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Bank of America raised their price objective on shares of Guardant Health from $135.00 to $190.00 and gave the stock a “buy” rating in a research note on Monday, July 6th. Piper Sandler lifted their price objective on shares of Guardant Health from $135.00 to $193.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 4th. TD Cowen boosted their target price on shares of Guardant Health from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Finally, JPMorgan Chase & Co. increased their target price on Guardant Health from $185.00 to $195.00 and gave the company an “overweight” rating in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $183.78.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.